Novo Nordisk A/S’s (NYSE:NVO) shared data Friday on its kidney outcomes trial, FLOW. The trial evaluated once-weekly injectable Ozempic for the treatment of type 2 diabetes. The FLOW (Evaluate Renal Function with Semaglutide Once Weekly) study included 3,533 patients with a median follow-up period of 3.4 years. In March, the company released headline data demonstrating a 24% reduction in kidney disease progression and cardiovascular and kidney death. Also Read: Novo Nordisk’s Once-Weekly Insulin Flagged With Risk Of Low Blood Sugar Ahead ...